Neogenomics Inc (NEO) 3.26 $NEO
NeoGenomics Selected by Aurora Diagnostics as Primary Partner for Molecular, FISH, and Immunohistochemistry Testing
PR Newswire - Thu May 08, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic and molecular testing services, announced today that it has been selected by Aurora Diagnostics to be its primary partner for molecular testing at each of Aurora's 19 specialized anatomic pathology laboratories in the United States.
NeoGenomics Reports Revenue of $18.2 Million and Adjusted EBITDA of $1.7 million for the First Quarter
PR Newswire - Wed Apr 23, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the first quarter of 2014.
NeoGenomics Schedules its Q1 2014 Earnings Release for April 23, 2014
PR Newswire - Thu Apr 03, 8:47AM CDT
NeoGenomics, Inc. (NASDAQ: NEO) announced today that it plans to release its first quarter 2014 financial results on Wednesday April 23, 2014.
4 Stocks Under $10 Making Big Moves
at The Street - Wed Apr 02, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
NeoGenomics Announces Next Generation Sequencing Tests for Solid Tumor Cancers and Myelodysplastic Syndrome
PR Newswire - Tue Mar 18, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic and molecular testing services, announced today that it has validated and launched the first two of a series of next generation cancer profiling tests. These tests are designed for profiling myelodysplastic syndrome (MDS) and solid tumor cancers. Additional cancer-type specific next generation tests are currently being validated and are scheduled for launch over the next several months.
NeoGenomics Reports Record Revenue of $18.3 Million, Adjusted EBITDA of $2.7 Million and Net Income of $0.02 per Share for the Fourth Quarter 2013
PR Newswire - Wed Feb 19, 6:00AM CST
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the fourth quarter and full year of 2013.
W&T Offshore Announces Year-End 2013 Reserves And Production, 2014 Capital Budget And Provides An Operations Update
PR Newswire - Fri Feb 14, 5:30AM CST
W&T Offshore, Inc. (NYSE: WTI) reported that the Company replaced in excess of 100% of 2013 production, that year-end 2013 SEC proved reserves(1) were 117.7 million barrels of oil equivalent ("MMBoe"
, and the pre-tax present value of these proved reserves discounted at 10%(1) ("PV-10" was $2.5 billion. In addition, it announced that its Board of Directors has approved a 2014 capital expenditure budget of $450 million, excluding acquisitions. The Company has also provided production for 2013 and an operational update for the fourth quarter of 2013 and early 2014.
4 Health Care Stocks Under $10 to Watch
at The Street - Fri Jan 31, 6:00AM CST
Keep these under-$10 health care stocks on your radar.
NeoGenomics Launches 22 New Cancer Genomic Tests Designed for Actionable Profiling of Various Hematologic and Solid Cancers
PR Newswire - Thu Jan 30, 6:00AM CST
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic and molecular testing services, announced today that it has validated and launched a series of NeoTYPE cancer profiling tests covering 22 different categories of cancer. Each of these tests is designed to investigate the most common and actionable genomic abnormalities reported for that particular tumor.
NeoGenomics Schedules its Q4 2013 and Full Year 2013 Earnings Release for February 19, 2014
PR Newswire - Fri Jan 17, 1:20PM CST
NeoGenomics, Inc. (NASDAQ: NEO) announced today that it plans to release its fourth quarter 2013 and full year 2013 financial results on Wednesday, February 19, 2014.
3 Health Care Stocks Under $10 Moving Higher
at The Street - Fri Jan 10, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
NeoGenomics is the First Laboratory to Offer Calreticulin (CALR) Mutation Testing for the Diagnosis and Classification of Myeloproliferative Neoplasms
PR Newswire - Tue Jan 07, 6:00AM CST
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has validated and launched a new test for the detection of mutations in the calreticulin (CALR) gene. The CALR gene is a novel biomarker that was reported to be specific for myeloproliferative neoplasms (MPN) for the first time at the annual meeting of the American Society of Hematology (ASH) last month. Since then, findings on the CALR gene have been published in the three articles referenced below.
Tower Companies Recognized as DOE Better Buildings Challenge Partner
PR Newswire - Wed Dec 18, 6:15AM CST
The Tower Companies announces that it has been recognized by the U.S. Department of Energy (DOE) for its commitment to reduce energy by 20% by 2020 for its entire commercial and residential portfolio as part of the Better Buildings Challenge. In addition, the U.S. Department of Energy and the US Department of Housing and Urban Development (HUD) also recognized Tower for becoming an inaugural partner of Better Buildings Challenge Multifamily Partners, the newly announced multifamily housing program expansion.
Covance Central Laboratories and NeoGenomics Enter into Exclusive Alliance to Provide Comprehensive Anatomic Pathology, Histology and Specialty Laboratory Testing Services for Clinical Trials
PR Newswire - Mon Nov 18, 6:00AM CST
Covance Inc. (NYSE: CVD), one of the world's largest and most comprehensive drug development services companies, and NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology-focused genetics testing services, today announced a strategic collaboration to jointly provide anatomic pathology and specialty laboratory testing services for global clinical trials.
OTC Daily Alert Stock Watch - NeoGenomics, Inc., (NASDAQ: NEO)
WorldStockWire - Thu Aug 29, 11:45PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
OTC Daily Alert Stock Watch - NeoGenomics, Inc (NASDAQ: NEO)
WorldStockWire - Fri Aug 16, 5:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
NeoGenomics Reports Revenue of $15.6 Million, Adjusted EBITDA of $1.8 Million and Earnings per share of $0.01 for the Second Quarter 2013
PR Newswire - Wed Jul 31, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the second quarter of 2013.
NeoGenomics Inc reports launch of comprehensive myelodysplastic syndrome (MDS) molecular tests
M2 - Fri Jul 26, 6:04AM CDT
Cancer testing company NeoGenomics Inc (NasdaqCM:NEO) reported on Thursday the availibility of several clinical molecular tests for the comprehensive profiling of myelodysplastic syndrome (MDS) following validation.
NeoGenomics Introduces Comprehensive Myelodysplastic Syndrome (MDS) Molecular Testing
PR Newswire - Thu Jul 25, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has validated and launched a number of clinical molecular tests for the comprehensive profiling of myelodysplastic syndrome (MDS).
Nasdaq stocks posting largest volume increases
AP - Mon Jul 22, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
NeoGenomics Selected by Aurora Diagnostics as Primary Partner for Molecular, FISH, and Immunohistochemistry Testing
PR Newswire - Thu May 08, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic and molecular testing services, announced today that it has been selected by Aurora Diagnostics to be its primary partner for molecular testing at each of Aurora's 19 specialized anatomic pathology laboratories in the United States.
NeoGenomics Reports Revenue of $18.2 Million and Adjusted EBITDA of $1.7 million for the First Quarter
PR Newswire - Wed Apr 23, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the first quarter of 2014.
NeoGenomics Schedules its Q1 2014 Earnings Release for April 23, 2014
PR Newswire - Thu Apr 03, 8:47AM CDT
NeoGenomics, Inc. (NASDAQ: NEO) announced today that it plans to release its first quarter 2014 financial results on Wednesday April 23, 2014.
4 Stocks Under $10 Making Big Moves
at The Street - Wed Apr 02, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
NeoGenomics Announces Next Generation Sequencing Tests for Solid Tumor Cancers and Myelodysplastic Syndrome
PR Newswire - Tue Mar 18, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic and molecular testing services, announced today that it has validated and launched the first two of a series of next generation cancer profiling tests. These tests are designed for profiling myelodysplastic syndrome (MDS) and solid tumor cancers. Additional cancer-type specific next generation tests are currently being validated and are scheduled for launch over the next several months.
NeoGenomics Reports Record Revenue of $18.3 Million, Adjusted EBITDA of $2.7 Million and Net Income of $0.02 per Share for the Fourth Quarter 2013
PR Newswire - Wed Feb 19, 6:00AM CST
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the fourth quarter and full year of 2013.
W&T Offshore Announces Year-End 2013 Reserves And Production, 2014 Capital Budget And Provides An Operations Update
PR Newswire - Fri Feb 14, 5:30AM CST
W&T Offshore, Inc. (NYSE: WTI) reported that the Company replaced in excess of 100% of 2013 production, that year-end 2013 SEC proved reserves(1) were 117.7 million barrels of oil equivalent ("MMBoe"
, and the pre-tax present value of these proved reserves discounted at 10%(1) ("PV-10" was $2.5 billion. In addition, it announced that its Board of Directors has approved a 2014 capital expenditure budget of $450 million, excluding acquisitions. The Company has also provided production for 2013 and an operational update for the fourth quarter of 2013 and early 2014. 4 Health Care Stocks Under $10 to Watch
at The Street - Fri Jan 31, 6:00AM CST
Keep these under-$10 health care stocks on your radar.
NeoGenomics Launches 22 New Cancer Genomic Tests Designed for Actionable Profiling of Various Hematologic and Solid Cancers
PR Newswire - Thu Jan 30, 6:00AM CST
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic and molecular testing services, announced today that it has validated and launched a series of NeoTYPE cancer profiling tests covering 22 different categories of cancer. Each of these tests is designed to investigate the most common and actionable genomic abnormalities reported for that particular tumor.
NeoGenomics Schedules its Q4 2013 and Full Year 2013 Earnings Release for February 19, 2014
PR Newswire - Fri Jan 17, 1:20PM CST
NeoGenomics, Inc. (NASDAQ: NEO) announced today that it plans to release its fourth quarter 2013 and full year 2013 financial results on Wednesday, February 19, 2014.
3 Health Care Stocks Under $10 Moving Higher
at The Street - Fri Jan 10, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
NeoGenomics is the First Laboratory to Offer Calreticulin (CALR) Mutation Testing for the Diagnosis and Classification of Myeloproliferative Neoplasms
PR Newswire - Tue Jan 07, 6:00AM CST
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has validated and launched a new test for the detection of mutations in the calreticulin (CALR) gene. The CALR gene is a novel biomarker that was reported to be specific for myeloproliferative neoplasms (MPN) for the first time at the annual meeting of the American Society of Hematology (ASH) last month. Since then, findings on the CALR gene have been published in the three articles referenced below.
Tower Companies Recognized as DOE Better Buildings Challenge Partner
PR Newswire - Wed Dec 18, 6:15AM CST
The Tower Companies announces that it has been recognized by the U.S. Department of Energy (DOE) for its commitment to reduce energy by 20% by 2020 for its entire commercial and residential portfolio as part of the Better Buildings Challenge. In addition, the U.S. Department of Energy and the US Department of Housing and Urban Development (HUD) also recognized Tower for becoming an inaugural partner of Better Buildings Challenge Multifamily Partners, the newly announced multifamily housing program expansion.
Covance Central Laboratories and NeoGenomics Enter into Exclusive Alliance to Provide Comprehensive Anatomic Pathology, Histology and Specialty Laboratory Testing Services for Clinical Trials
PR Newswire - Mon Nov 18, 6:00AM CST
Covance Inc. (NYSE: CVD), one of the world's largest and most comprehensive drug development services companies, and NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology-focused genetics testing services, today announced a strategic collaboration to jointly provide anatomic pathology and specialty laboratory testing services for global clinical trials.
OTC Daily Alert Stock Watch - NeoGenomics, Inc., (NASDAQ: NEO)
WorldStockWire - Thu Aug 29, 11:45PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
OTC Daily Alert Stock Watch - NeoGenomics, Inc (NASDAQ: NEO)
WorldStockWire - Fri Aug 16, 5:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
NeoGenomics Reports Revenue of $15.6 Million, Adjusted EBITDA of $1.8 Million and Earnings per share of $0.01 for the Second Quarter 2013
PR Newswire - Wed Jul 31, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the second quarter of 2013.
NeoGenomics Inc reports launch of comprehensive myelodysplastic syndrome (MDS) molecular tests
M2 - Fri Jul 26, 6:04AM CDT
Cancer testing company NeoGenomics Inc (NasdaqCM:NEO) reported on Thursday the availibility of several clinical molecular tests for the comprehensive profiling of myelodysplastic syndrome (MDS) following validation.
NeoGenomics Introduces Comprehensive Myelodysplastic Syndrome (MDS) Molecular Testing
PR Newswire - Thu Jul 25, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has validated and launched a number of clinical molecular tests for the comprehensive profiling of myelodysplastic syndrome (MDS).
Nasdaq stocks posting largest volume increases
AP - Mon Jul 22, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
